Viral hepatitis prevention by immunization

Jornal de Pediatria

Volumn 82, Issue SUPPL. 1, 2006, Pages

  Ferreira, Cristina Targa ^a,b   Da Silveira, Themis Reverbel ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b UFRGS ^*  (Brazil)

Author keywords

Hepatitis A; Hepatitis B; Immunization; Vaccines

Indexed keywords

EUVAX; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE;

ACUTE DISEASE; CHRONIC LIVER DISEASE; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE POLICY; HEPATITIS A; HEPATITIS B; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; INFECTION RISK; MASS IMMUNIZATION; NONHUMAN; PRACTICE GUIDELINE; PREVALENCE; REVIEW; TREATMENT RESPONSE; VIRUS HEPATITIS;

CHILD, PRESCHOOL; FEMALE; HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; MASS IMMUNIZATION; PREGNANCY; VACCINATION;

EID: 33750499067     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/JPED.1500     Document Type: Review

References (73)

1. Schiff ER. Introduction. Am J Med. 2005;118 Suppl 10A:1S-6S.
2. Brasil, Secretaria de Políticas de Saúde. Hepatites virais - o Brasil está atento. Normas e manuais técnicos. Brasília: Ministério da Saúde; 2003.
3. Expanded programme on immunization. Global advisory group - Part 1. Wkly Epidemiol Rec. 1992;67:11-5.
4. Center for Disease Control and Prevention (CDC). Hepatitis surveillance report no. 59. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2004. http://www.cdc.gov/ncidod/diseases/ hepatitis/resource/. Access: 08/02/2006.
5. Clemens SAC, da Fonseca JC, Azevedo T, Cavalcanti A, Silveira TR, Castilho MC, et al. Soroprevalência para hepatite A e hepatite B em 4 centros no Brasil. Rev Soc Bras Med Trop. 2000;33:1-10.
6. Davis JP. Experience with hepatitis A and B vaccines. Am J Med. 2005:118 Suppl 10A:7S-15S.
7. Poland GA. Evaluating existing recommendations for hepatitis A and B vaccination. Am J Med. 2005;118 Suppl 10A:16S-20S.
8. Provost PJ, Hilleman MR. Propagation of human hepatitis A virus in cell culture in vitro. Proc Soc Exp Biol Med. 1979;160:213-21.
9. Andre FE. Approaches to a vaccine against hepatitis A: development and manufacture of an inactivated vaccine. J Infect Dis. 1995;171 Suppl 1:S33-9.
10. Andre FE, D'Hondt E, Delem A, Safary A. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine. 1992;10 Suppl 1:S160-8.
11. Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA, et al. Protection against hepatitis A by an inactivated vaccine. JAMA. 1994;271:1328-34.
12. Werzberger A, Mensch B, Kuter B, Brown L, Lewis J, Sitrin R, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med. 1992;327:453-7.
13. Ginsberg GM, Slater PE, Shouval D. Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity. J Hepatol. 2001;34:92-9.
14. Van Damme P, Thoelen S, Cramm M, De Groote K, Safary A, Meheus A. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol. 1994;44:446-51.
15. Fujiyama S, Odoh K, Kuramoto I, Mizuno K, Tsurusaki R, Sato T. Current seroepidemiological status of hepatitis A with comparison of antibodies titers after infection and vaccination. J Hepatol. 1994;21:641-5.
16. Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, Andre FE. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis. 1995;171 Suppl 1:S44-9.
17. Keeffe EB, Iwarson S, McMahon BJ, Lindsay KL, Koff RS, Manns M, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology. 1998;27:881-6.
18. Van Herck K, Beutels P, Van Damme P, Beutels M, Van den Dries J, Briantais P, et al. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccine. J Med Virol. 2000;60:1-7.
19. Cederna JB, Klinzman D, Stapleton JT. Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine. Vaccine. 1999;18:892-8.
20. Wiedermann G, Kundi M, Ambrosch F, Safary A, D'Hont E, Delem A. Inactivated hepatitis A vaccine: long-term antibody persistence. Vaccine. 1997;15:612-5.
21. Prevention of hepatitis A through active and passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1999;48(RR-12):1-37.
22. Mast EE, Margolis HS, Fiore AE, Brinck EW, Goldstein W, Wang SA, et al. A comprehensive immunization strategy eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP) - Part 1: Immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54:1-31.
23. Hess G, Clemens R, Bienzle U, Schonfeld C, Schunk B, Bock HL. Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men. J Med Virol. 1995;46:40-2.
24. Gouvea AF, De Moraes-Pinto MI, Ono E, Dinnelli MI, Machado DM, Weckx LY, et al. Immunogenicity and tolerability of hepatitis A vaccine in HIV-infected children. Clin Infect Dis. 2005;41:544-8.
25. Gouvea AF, De Moraes-Pinto MI, Machado DM, Carmo FB, Beltrao SC, Cunegundes KS, et al. Prevalência de anticorpos contra o vírus da hepatite A em crianças e adolescentes expostos e/ou infectados pelo HIV. J Pediatr (Rio J). 2005;81:205-8.
26. Santagostino E, Gringeri A, Rocino A, Zanetti A, de Biasi R, Mannucci PM. Patterns of immunogenicity of an inactivated hepatitis A vaccine in anti-HIV positive and negative hemophilia patients. Thromb Haemost. 1994;72:508-10.
27. Kemper CA, Haubrich R, Frank I, Dubin G, Buscarino C, McCutchan JA, et al. Safety and immunogenicity of hepatitis A in human immunodeficiency virus-infected patients: a double blind randomized, placebo-controlled trial. J Infect Dis. 2003;187:1327-31.
28. Arslan M, Wiesner RH, Poterucha JJ, Zein NN. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation. 2001;72:272-6.
29. Canero-Velasco MC, Mutti JE, Nucifora S, Alvarez K, Antonuccio MC, Sosa A, et al. Safety and immunogenicity after hepatitis A vaccination in pediatric chronic renal disease patients. J Pediatr Gastroenterol Nutr. 2000;31(Suppl 2):S54.
30. Stark K, Gunther M, Neuhaus R, Reinke P, Schroder K, Linnig S, et al. Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. J Infect Dis. 1999;180:2014-7.
31. Bell BP. Hepatitis A and hepatitis B vaccination of patients with chronic liver disease. Acta Gastroenterol Belg. 2000;63:359-63.
32. Schwarz KB, Balistreri W. Viral hepatitis. In: American Liver Foundation. Pediatric Liver Research Agenda 2000: a blueprint for the future research goals and strategies to treat prevent and conquer childhood liver diseases. New York: American Liver Foundation; 2000. p. 56-63.
33. Keeffe EB. Acute hepatitis A and B in patients with chronic liver disease: prevention through vaccination. Am J Med 2005:118 Suppl 10A:21S-27S.
34. Arguedas MR, Johnson A, Eloubeidi MA, Fallon MB. Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients. Hepatology. 2001;34:28-31.
35. Ferreira CT, Leite JC, Taniguchi A, Vieira SM, Pereira-Lima J, Silveira TR. Immunogenicity and safety of hepatitis A vaccine in Down syndrome children. J Pediatr Gastroenterol Nutr. 2004;39:337-40.
36. Ferreira CT, da Silveira TR, Vieira SM, Taniguchi AN, Pereira-Lima J. Immunogenicity and safety of hepatitis A vaccine in children with chronic liver disease. J Pediatr Gastroenterol Nutr. 2003;37:258-61.
37. Ferreira CT, Taniguchi AN, Vieira SM, Pereira-Lima J, da Silveira TR. Prevalência do anticorpo da hepatite A em hepatopatia crônica. J Pediatr (Rio J). 2002;78:503-8.
38. Nebbia G, Giacchino R, Soncini R, Ramaccioni V, Timitilli A, Zanetti AR. Hepatitis A vaccination in chronic carriers of hepatitis B virus. J Pediatr. 1999;134:784-5.
39. McMahon BJ, Beller M, Williams J, Schloss M, Tanttila H, Bulkow L. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch Pediatr Adolesc Med. 1996;150:733-9.
40. Zamir C, Rishpon S, Zamir D, Leventhal A, Rimon N, Ben-Porath E. Control of a community-wide outbreak of hepatitis A by mass vaccination with inactivated hepatitis A vaccine. Eur J Clin Microbiol Infect Dis. 2001;20:185-7.
41. Tapia-Conyer R, Santos JI, Cavalcanti AM, Urdaneta E, Rivera L, Manterola A, et al. Hepatitis A in Latin America: a changing epidemiologic pattern. Am J Trop Med Hyg. 1999;61:825-9.
42. Acharya SK, Batra Y, Bhatkal B, Ojha B, Kaur K, Hazari S, et al. Seroepidemiology of hepatitis A virus infection among school children in Delhi and north Indian patients with chronic liver disease: implications for HAV vaccination. J Gastroent Hepatol. 2003;18:822-7.
43. Ferreira CT, Silva GL, Barros FC, Pereira-Lima J. Soroepidemiologia da hepatite A em dois grupos populacionais economicamente distintos de Porto Alegre. GED. 1996;15:85-90.
44. Gomes MAC. Hepatite A: prevalência e fatores de risco na população escolar de São Luís, MA [dissertaç ão]. São Luís: Universidade Federal do Maranhão; 2004.
45. Das A. An economic analysis of different strategies of immunization against hepatitis A virus in developed countries. Hepatology. 1999;29:548-52.
46. Rosenthal P. Cost-effectiveness of hepatitis A vaccination in children, adolescents and adults. Hepatology. 2003;37:44-51.
47. Jacobs RJ, Greenberg DP, Koff RS, Saab S, Meyerhoff AS. Regional variation in the cost effectiveness of childhood hepatitis A immunization. Pediatr Infect Dis J. 2003;22:904-14.
48. Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel followings B universal immunization of toddlers. JAMA. 2005;294:202-10.
49. Hanna JN, Hills SL, Humphreys JL. Impact of hepatitis A vaccination of indigenous children on notifications of hepatitis A in north Queensland. Med J Aust. 2004;181:482-5.
50. Bell BP. Hepatitis A vaccine. Pediatr Infet Dis J. 2000;19:1187-8.
51. Ciocca M, Porta G, Silveira TR, Moreira-Silva S. Hepatitis A as an etiological agent of acute liver failure in Latin America. Pediatr Infect Dis J. In press.
52. Petersen KM, Bulkow LR, McMahon BJ, Zanis C, Getty M, Peters H, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J. 2004;23:650-5.
53. Lok AS. The maze of treatments for hepatitis B. N Engl J Med. 2005;352:2743-6.
54. Shete PB, Daum RS. Real versus theoretical: assessing the risks and benefits of postponing the hepatitis B vaccine birth dose. Pediatrics. 2002;109:701-3.
55. Center for Disease Control and Prevention. Hepatitis B. In: Atkinson W, Hamborsky J, Wolfe C, editors. Epidemiology and prevention of vaccine-preventable diseases. 8th ed. Washington: Public Health Foundation; 2004. p. 191-212.
56. Sadeck LSR, Ramos JLA. Resposta imune à vacinação contra hepatite B em recém-nascidos pré-termo, iniciada no primeiro dia de vida. J Pediatr (Rio J). 2004;80:113-8.
57. Duval B, Gilca V, Boulianne N, De Wals P, Masse R, Trudeau G, et al. Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after 5 years in a low endemicity country. Pediatr Infec Dis J. 2005;24:213-8.
58. Gong XH, Wang FZ, Li H, Liu LR, Li YH, Wang BL, et al. Observation on effects of hepatitis B vaccine immunization for 12 years in children in Beijing. Zhonghua Yu Fang Yi Xue Za Zhi. 2005;39:265-8.
59. Zanetti AR, Mariano A, Romano L, D'Amelio R, Chironna M, Coppola RC, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005;366:1379-84.
60. Chang MH. New insights in hepatitis B virus infection. Int Semin Pediatr Gastroenterol Nutr. 2004;12:9-14.
61. Poovorawan Y, Sanpavat S, Pongpunglert W, Chumdermpadetsuk S, Sentrakul P, Vandepapeliere P, et al. Long-term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J. 1992;11:816-21.
62. Poovorawan Y, Theamboonlers A, Vimolket T, Sinlaparatsamee S, Chaiear K, Siraprapasiri T, et al. Impact of hepatitis B immunisation as part of Thailand's EPI. Vaccine. 2000;19:943-9.
63. Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C, Michel ML. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology. 2004;40:874-82.
64. Patwardhan A, Jamjute P, Peter. Foetal immunoprophylaxis with hepatitis B vaccine could be a cost-effective approach towards eradication in the high-risk population: PH2-02. J Pediatr Gastroenterol Nutr. 2005;40:678.
65. François G, Duclos P, Margolis H, Lavanchy D, Siegrist CA, Meheus A, et al. Vaccine safety controversies and the future of vaccination programs. Pediatr Infect Dis J. 2005;24:953-61.
66. Kapoor D, Aggarwal SR, Singh NP, Thakur V, Sarin SK. Granulocyte- macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients. J Viral Hepat. 1999;6:405-9.
67. Wilson CM, Ellenberg JH, Sawyer MK, Belzer M, Crowley-Nowick PA, Puga A, et al. Serologic response to hepatitis B vaccine in HIV infected and high risk HIV uninfected adolescents in REACH cohort. Reaching for excellence in adolescent care and health. J Adolesc Health. 2001;29(3 Suppl):123-9.
68. Silveira TR, Cunha J, Krebs LS, Ramalho L. Avaliação do grau de conhecimento e de proteção de ginecologistas e obstetras do Rio Grande do Sul em relação à hepatite B. Rev AMRIGS. 2003;47:193-201.
69. Chen HL, Chang CJ, Kong MS, Huang FC, Lee HC, Lin CC, et al. Fulminant hepatic failure in children in endemic areas of hepatitis B virus infection: 15 years after universal hepatitis B vaccination. Hepatology. 2004;39:58-63.
70. Boxall EH, Sira J, Standish RA, Davies P, Sleight E, Dhillon AP, et al. Natural history of hepatitis B in perinatally infected carriers. Arch Dis Child Fetal Neonatal Ed. 2004;89:F456-60.
71. Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med. 2001;135:796-800.
72. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med. 1997;336:1855-9.
73. Bensabath G, Soares MCP. A evolução do conhecimento sobre as hepatites virais na região amazônica: da epidemiologia e etiologia à prevenção. Rev Soc Bras Med Trop. 2004;37(Supl II):14-36.